Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (RTOG 1205)
- At least 18 years of age
- Diagnosis of Recurrent Glioblastoma or Gliosarcoma
- Adequate labs
- History and Physical, including neurologic examination done 14 days prior to registration
- Patients must be able to undergo brain MRI scans with intravenous gadolinium
- Patients who have completed a course of radiation therapy at least 6 months prior
Please contact Jamie Holt at (520) 626-6800 for further information regarding our clinical trials.
An Institutional Review Board responsible for human subjects research at The University of Arizona reviewed this research project and found it to be acceptable, according to applicable state and federal regulations and University policies designed to protect the rights and welfare of participants in research.